VEGFA and age-related macular degeneration: Previously, Minturn et al. noted a significant decrease in CST demonstrating potential benefits of sirolimus in persistent, exudative AMD; however, the study was limited by small cohort size, safety concerns, and the need for some subjects to be rescued from sirolimus to anti-VEGF [12].